Experiment & Theory to Test an Evolutionary Fitness Role for Lentiviral Latency

实验

基本信息

  • 批准号:
    8891364
  • 负责人:
  • 金额:
    $ 24.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-15 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): There is a fundamental gap in our knowledge as to why lentiviruses, such as the human immunodeficiency virus type 1 (HIV-1), enter latency and whether latency plays any role in the natural history of infection. This information is critically needed to identify the mechanism of resilience of the latent reservoir. HIV-1 has killed 30 million people worldwide, 36 million people are living with HIV-1/AIDS, and there is no effective vaccine for HIV-1. The available antiretroviral therapies (ARTs) for treating HIV-1 cannot cure infected patients because HIV-1 enters a dormant state by latently infecting CD4+ T cells. The resulting latent reservoirs are long lived, ensuring lifelong persistence of the virus, and are recognized as the greatest obstacle to an HIV-1 cure. The prevailing and accepted view is that latency is an "accident" manifested by ART and carries no fitness benefit for the virus in the natural history of infection (i.e., it is not an evolved trait of the virus). However, there is no evidence to supportthis view that latency is an accident and alternative therapy strategies might be more effective than current strategies if latency provides a fitness benefit for the virus. The long-term goal is to design alternative therapy strategies to address the problem of HIV-1 latency. The immediate objective of this proposal is to determine if latency provides a fitness benefit for HIV-1. Based o recent studies showing that initial infection at the mucosal membrane is a harsh environment for the virus, our central hypothesis is that latency confers a selective advantage for the virus by protecting it against harsh conditions during initial infection at mucosal membranes. The rationale for this project is that the knowledge acquired will help to identify new therapeutic approaches. To achieve our objective, we will develop a multi- scale quantitative model linking latency to virus transmission and test this model in a novel experimental cell- culture system. The proposed research will break new ground in the long-term HIV latency problem. It will be the first effort to apply modern theoretical tools of viral evolution to test a fitness role for HI-1 latency. This contribution is significant, because if latency confers a fitness advantage to HIV-1, current eradication strategies are fighting an evolved viral phenotype, which is likely to be exceptionally challenging. Determining if latency is an evolved trait it would substantially alter HIV-1 cure research from eradication (e.g. 'activate-and-kill' approaches) to containment strategies (which could represent a 'functional cure').
描述(由申请人提供):为什么慢病毒,如人类免疫缺陷病毒1型(HIV-1)会进入潜伏期,以及潜伏期是否在感染的自然史中起任何作用,在我们的知识中存在根本性的空白。这一信息对于确定潜在水库的恢复机制至关重要。HIV-1已导致3000万人死亡

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Spatial tuning of acoustofluidic pressure nodes by altering net sonic velocity enables high-throughput, efficient cell sorting.
通过改变净声速来空间调整声流体压力节点可实现高通量、高效的细胞分选。
  • DOI:
    10.1039/c4lc01342e
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Jung,Seung-Yong;Notton,Timothy;Fong,Erika;Shusteff,Maxim;Weinberger,LeorS
  • 通讯作者:
    Weinberger,LeorS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leor S Weinberger其他文献

Leor S Weinberger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leor S Weinberger', 18)}}的其他基金

A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups
HIV基因驱动疗法:针对高危人群的单次给药干预
  • 批准号:
    10404422
  • 财政年份:
    2021
  • 资助金额:
    $ 24.15万
  • 项目类别:
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups
HIV基因驱动疗法:针对高危人群的单次给药干预
  • 批准号:
    10596543
  • 财政年份:
    2020
  • 资助金额:
    $ 24.15万
  • 项目类别:
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups
HIV基因驱动疗法:针对高危人群的单次给药干预
  • 批准号:
    10597282
  • 财政年份:
    2020
  • 资助金额:
    $ 24.15万
  • 项目类别:
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups
HIV基因驱动疗法:针对高危人群的单次给药干预
  • 批准号:
    10377987
  • 财政年份:
    2020
  • 资助金额:
    $ 24.15万
  • 项目类别:
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups
HIV基因驱动疗法:针对高危人群的单次给药干预
  • 批准号:
    10381365
  • 财政年份:
    2020
  • 资助金额:
    $ 24.15万
  • 项目类别:
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups
HIV基因驱动疗法:针对高危人群的单次给药干预
  • 批准号:
    10163412
  • 财政年份:
    2020
  • 资助金额:
    $ 24.15万
  • 项目类别:
A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups
HIV基因驱动疗法:针对高危人群的单次给药干预
  • 批准号:
    10782797
  • 财政年份:
    2020
  • 资助金额:
    $ 24.15万
  • 项目类别:
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics
调节随机基因表达以控制细胞命运和治疗
  • 批准号:
    10211509
  • 财政年份:
    2014
  • 资助金额:
    $ 24.15万
  • 项目类别:
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics
调节随机基因表达以控制细胞命运和治疗
  • 批准号:
    10581483
  • 财政年份:
    2014
  • 资助金额:
    $ 24.15万
  • 项目类别:
Stochastic Gene Expression in Retroviral Latency
逆转录病毒潜伏期的随机基因表达
  • 批准号:
    9285693
  • 财政年份:
    2014
  • 资助金额:
    $ 24.15万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 24.15万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 24.15万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 24.15万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 24.15万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 24.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 24.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 24.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 24.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 24.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 24.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了